Susana Inmaculada
Inoges Sancho
Consultora Médica
Clínica Universitaria de Navarra
Pamplona, EspañaClínica Universitaria de Navarra -ko ikertzaileekin lankidetzan egindako argitalpenak (20)
2021
2020
-
Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression
British Journal of Haematology, Vol. 189, Núm. 6, pp. 1064-1073
2019
-
Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach
British Journal of Clinical Pharmacology, Vol. 85, Núm. 8, pp. 1670-1683
2017
-
A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients
Journal of Translational Medicine, Vol. 15, Núm. 1
-
Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA)
PLoS ONE, Vol. 12, Núm. 9
2016
-
Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity
Immunologic Research, Vol. 64, Núm. 2, pp. 548-557
-
Tumor-Produced Interleukin-8 Attracts human myeloid-derived suppressor cells and elicits extrusion of Neutrophil Extracellular Traps (NETs)
Clinical Cancer Research, Vol. 22, Núm. 15, pp. 3924-3936
2008
-
IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis
European Journal of Immunology, Vol. 38, Núm. 2, pp. 576-586
2007
-
Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor
Journal of Biological Chemistry, Vol. 282, Núm. 10, pp. 7405-7415
-
Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions
Journal of Investigative Dermatology, Vol. 127, Núm. 7, pp. 1673-1680
-
La terapia celular antitumoral
Gastroenterologia y Hepatologia Continuada
2006
-
Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma
Journal of the National Cancer Institute, Vol. 98, Núm. 18, pp. 1292-1301
2004
-
Imatinib Inhibits Proliferation of Ewing Tumor Cells Mediated by the Stem Cell Factor/KIT Receptor Pathway, and Sensitizes Cells to Vincristine and Doxorubicin-Induced Apoptosis
Clinical Cancer Research, Vol. 10, Núm. 2, pp. 751-761
-
Imatinib mesylate in cutaneous melanoma [7]
Journal of Investigative Dermatology
-
Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: Implications for anti-idiotype vaccine development
Critical Reviews in Oncology/Hematology, Vol. 52, Núm. 1, pp. 1-7
2003
-
Estrategias terapéuticas con vacunas idiotípicas en el tratamiento del linfoma folicular
Hematologia - Citocinas, Inmunoterapia y Terapia Celular, Vol. 6, Núm. 3, pp. 175-182
-
Feasibility of idiotype vaccination in relapsed B-cell malignancies
Haematologica, Vol. 88, Núm. 12, pp. 1438-1440
2001
2000
-
Clinico-pathologic, immunohistochemical, and TUNEL study in early cardiac allograft failure
Cardiovascular Pathology, Vol. 9, Núm. 3, pp. 153-159
1998
-
Progressive decrease of CD8(high+) CD28+ CD57- cells with ageing
Clinical and Experimental Immunology, Vol. 112, Núm. 1, pp. 48-51